Concepedia

Mario Grisanti

MG

Statistics

Publications

25

Citations

2.8K

H-Index

23

Active since

1997

Affiliations

Amgen (United States)(Current)

Geriatric Research Education and Clinical Center

University of California, Los Angeles

Institute of Cell Biology

VA Sepulveda Ambulatory Care Center

Mario Grisanti is an author at Amgen (United States) specializing in bone metabolism, medicine, and bone health.

Publications per year

1997–2023

25

Publications

25

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL

Paul J. Kostenuik, Hung Q. Nguyen, James McCabe et al. · Journal of Bone and Mineral Research · 2008 · 436 citations

Medicine, Immunology, Molecular Medicine +17

Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia

Ji Li, Ildiko Sarosi, Russell C. Cattley et al. · Bone · 2006 · 434 citations

Medicine, Orthopedic Surgery, Bone Metabolism +11

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair

Mónica Florio, Kannan Gunasekaran, Marina Stolina et al. · Nature Communications · 2016 · 253 citations · Full text

Pharmacy, Biochemistry, Molecular Biology +17

Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats

Xiaodong Li, Kelly Warmington, Qing‐Tian Niu et al. · Journal of Bone and Mineral Research · 2010 · 234 citations

Medicine, Orthopaedic Surgery, Bone Augmentation +16

Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

Gisela Ruiz Heiland, Karin Zwerina, Wolfgang Baum et al. · Annals of the Rheumatic Diseases · 2010 · 204 citations

Medicine, Immunology, Pathobiology +17

1–5 of 25